Cargando…
Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma
Multiple myeloma (MM) is a hematological malignancy that remains incurable because most patients eventually relapse or become refractory to current treatments. Although the treatments have improved, the major problem in MM is resistance to therapy. Clonal evolution of MM cells and bone marrow microe...
Autores principales: | Yang, Wen-Chi, Lin, Sheng-Fung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663284/ https://www.ncbi.nlm.nih.gov/pubmed/26649299 http://dx.doi.org/10.1155/2015/341430 |
Ejemplares similares
-
The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma
por: Vo, Josh N., et al.
Publicado: (2022) -
Carfilzomib for relapsed and refractory multiple myeloma
por: Groen, K, et al.
Publicado: (2019) -
Treatment of relapsed and refractory multiple myeloma
por: Lee, Ji Hyun, et al.
Publicado: (2020) -
Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
por: Huang, Shang-Yi, et al.
Publicado: (2019) -
Lenalidomide for the treatment of relapsed and refractory multiple myeloma
por: van de Donk, Niels WCJ, et al.
Publicado: (2012)